Understanding FLiRT COVID Variants and Their Impact
The FLiRT variants of the SARS-CoV-2 virus, causing COVID-19, have dominated globally this year, according to the World Health Organization. FLiRT stands for the mutations' locations on the virus' spike protein. In the U.S., the KP.2 variant has become the most common in the past month, as per the CDC.
The FLiRT variants of the SARS-CoV-2 virus, causing COVID-19, have dominated globally this year, according to the World Health Organization.
FLiRT stands for the mutations' locations on the virus' spike protein.
In the U.S., the KP.2 variant has become the most common in the past month, as per the CDC.
These variants, including KP.2's lineage JN.1, possess three key spike protein mutations that may help them evade antibodies.
Dr. Aaron Glatt from Mount Sinai South Nassau Hospital observed no increase in severe illness or hospitalizations due to these variants, likely due to existing immunity from prior infections and vaccinations.
CDC data shows a decline in COVID-related hospitalizations and steady emergency department figures.
Current vaccines are expected to remain effective against FLiRT variants.
Since 2022, vaccine makers have been asked to update vaccines to target new variants.
Europe's regulator recommended targeting JN.1, and U.S. regulators will discuss vaccine design on June 5.
Pfizer, BioNTech, and Moderna await this meeting to finalize their vaccine designs, while Novavax has started producing a shot for JN.1 as per European guidelines.
FLiRT stands for the mutations' locations on the virus' spike protein.
In the U.S., the KP.2 variant has become the most common in the past month, as per the CDC.
These variants, including KP.2's lineage JN.1, possess three key spike protein mutations that may help them evade antibodies.
Dr. Aaron Glatt from Mount Sinai South Nassau Hospital observed no increase in severe illness or hospitalizations due to these variants, likely due to existing immunity from prior infections and vaccinations.
CDC data shows a decline in COVID-related hospitalizations and steady emergency department figures.
Current vaccines are expected to remain effective against FLiRT variants.
Since 2022, vaccine makers have been asked to update vaccines to target new variants.
Europe's regulator recommended targeting JN.1, and U.S. regulators will discuss vaccine design on June 5.
Pfizer, BioNTech, and Moderna await this meeting to finalize their vaccine designs, while Novavax has started producing a shot for JN.1 as per European guidelines.
